Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
PET imaging
clinical trials
medical oncology
nuclear medicine
prostate-specific membrane antigen (PSMA)
radiation therapy
radiology
radionuclides
radiopharmaceuticals
urology
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
22
07
2020
accepted:
23
07
2020
pubmed:
1
9
2020
medline:
14
1
2021
entrez:
1
9
2020
Statut:
ppublish
Résumé
The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY. The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer. Several major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT. This article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.
Identifiants
pubmed: 32865839
doi: 10.1002/pros.24056
pmc: PMC8442561
mid: NIHMS1733841
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1273-1296Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA134675
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184228
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
J Med Chem. 2001 Feb 1;44(3):298-301
pubmed: 11462970
Nucl Med Mol Imaging. 2017 Sep;51(3):202-211
pubmed: 28878845
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
J Magn Reson Imaging. 2017 Feb;45(2):579-585
pubmed: 27391860
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
pubmed: 12359855
J Nucl Med. 2019 Jul;60(7):950-954
pubmed: 30552200
Eur Urol Focus. 2019 Nov;5(6):998-1006
pubmed: 29609897
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
J Nucl Med. 2019 Jul;60(7):971-977
pubmed: 30683768
J Nucl Med. 2020 Jun;61(6):857-865
pubmed: 31732676
J Nucl Med. 2018 Sep;59(9):1406-1411
pubmed: 29371407
J Urol. 2004 Jul;172(1):133-6
pubmed: 15201753
J Nucl Med. 2017 Sep;58(9):1442-1449
pubmed: 28450562
J Clin Oncol. 2015 Apr 20;33(12):1356-63
pubmed: 25624432
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Lancet Oncol. 2019 Mar;20(3):408-419
pubmed: 30738780
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Urol Oncol. 2020 Nov;38(11):848.e9-848.e16
pubmed: 32600929
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
J Nucl Med. 2014 Apr;55(4):574-81
pubmed: 24578240
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
NeuroRx. 2004 Jul;1(3):307-16
pubmed: 15717032
Clin Cancer Res. 2015 Dec 1;21(23):5277-85
pubmed: 26175541
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Blood. 2017 May 11;129(19):2616-2623
pubmed: 28251914
Nat Commun. 2020 May 26;11(1):2641
pubmed: 32457376
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
J Nucl Med. 2018 Nov;59(11):1665-1671
pubmed: 29602821
Oncotarget. 2017 Jul 6;8(33):55094-55103
pubmed: 28903405
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):50-6
pubmed: 21932117
Cancer Imaging. 2020 Mar 14;20(1):23
pubmed: 32169115
J Nucl Med. 2018 Dec;59(12):1857-1864
pubmed: 30190304
Eur Urol. 2020 Nov;78(5):671-679
pubmed: 32317181
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
J Nucl Med. 2019 Apr;60(4):517-523
pubmed: 30291192
J Nucl Med. 2018 Mar;59(3):479-485
pubmed: 28887401
Oncotarget. 2016 Mar 15;7(11):12477-88
pubmed: 26871285
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
J Nucl Med. 2005 May;46(5):850-8
pubmed: 15872360
Oncotarget. 2017 Apr 18;8(16):26344-26355
pubmed: 28412751
Clin Genitourin Cancer. 2016 Feb;14(1):e115-8
pubmed: 26603549
J Nucl Med. 2020 May;61(5):729-734
pubmed: 31628219
Clin Nucl Med. 2019 Dec;44(12):e629-e633
pubmed: 31689286
Theranostics. 2017 Apr 10;7(6):1770-1780
pubmed: 28529650
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Clin Nucl Med. 2020 Jul;45(7):e309-e310
pubmed: 32404709
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1841-1851
pubmed: 29623376
Clin Cancer Res. 2020 Jun 15;26(12):2774-2776
pubmed: 32253231
J Nucl Med. 2018 Jun;59(6):871-877
pubmed: 29545375
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Int J Mol Sci. 2019 Oct 02;20(19):
pubmed: 31581638
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126071
J Urol. 2003 Dec;170(6 Pt 2):S84-8; discussion S88-9
pubmed: 14610416
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955
pubmed: 31932492
Cancer Res. 1997 Sep 1;57(17):3629-34
pubmed: 9288760
Lancet Oncol. 2012 Jan;13(1):43-54
pubmed: 22169269
J Urol. 2018 Jan;199(1):126-132
pubmed: 28736318
J Exp Med. 2018 Jan 2;215(1):159-175
pubmed: 29141866
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
Prostate. 2018 Aug;78(11):775-789
pubmed: 29717499
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2322-2327
pubmed: 32140802
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
J Urol. 2018 Jul;200(1):95-103
pubmed: 29409824
Clin Cancer Res. 2007 May 1;13(9):2707-13
pubmed: 17473203
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
J Clin Oncol. 2005 Jul 20;23(21):4591-601
pubmed: 15837970
Oncotarget. 2018 Dec 28;9(102):37676-37688
pubmed: 30701023
Clin Cancer Res. 2013 Sep 15;19(18):5182-91
pubmed: 23714732
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Mol Cancer Ther. 2020 Jan;19(1):13-25
pubmed: 31534013
Lancet Oncol. 2014 Jun;15(7):738-46
pubmed: 24836273
Eur Radiol. 2016 Dec;26(12):4345-4353
pubmed: 27011373
Nat Rev Urol. 2016 Apr;13(4):226-35
pubmed: 26902337
Cancer Discov. 2019 May;9(5):646-661
pubmed: 30777870
Nat Rev Urol. 2020 Feb;17(2):107-118
pubmed: 31937920
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076-1077
pubmed: 29445927
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
J Nucl Med. 2016 Jan;57(1):151-62
pubmed: 26471692
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24
pubmed: 21324610
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S
pubmed: 28864615
JCO Precis Oncol. 2020;4:370-381
pubmed: 32462107
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Front Oncol. 2012 Sep 06;2:104
pubmed: 22973551
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
BMC Cancer. 2019 Jan 7;19(1):18
pubmed: 30616601
Nat Biomed Eng. 2017;1:977-982
pubmed: 29456877
Eur Urol Oncol. 2019 Nov;2(6):670-676
pubmed: 31412006
Nucl Med Commun. 2018 Nov;39(11):1013-1021
pubmed: 30216228
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
BJU Int. 2019 Oct;124(4):551-553
pubmed: 31127664
Semin Nucl Med. 2020 Mar;50(2):133-140
pubmed: 32172798
Angew Chem Int Ed Engl. 2008;47(17):3196-201
pubmed: 18366035
J Pharm Pharmacol. 2016 Jul;68(7):912-21
pubmed: 27139157
Prostate. 2000 May 1;43(2):150-7
pubmed: 10754531
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Eur Radiol. 2018 Dec;28(12):5275-5283
pubmed: 29846803
Int J Radiat Biol. 2018 Aug;94(8):743-751
pubmed: 28967281
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
J Clin Oncol. 2004 Jul 1;22(13):2522-31
pubmed: 15173215
Sci Rep. 2016 Jan 12;6:19049
pubmed: 26754564
Oncotarget. 2016 Dec 13;7(50):82504-82510
pubmed: 27756888
Clin Oncol (R Coll Radiol). 2007 Jun;19(5):289-301
pubmed: 17517328
Clin Cancer Res. 1999 Oct;5(10):2674-81
pubmed: 10537328
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):38-52
pubmed: 31595044
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
J Clin Oncol. 2010 Jul 20;28(21):e355-6; author reply e357
pubmed: 20458048
J Nucl Med. 2017 Aug;58(8):1196-1200
pubmed: 28663195
Clin Cancer Res. 2015 Feb 15;21(4):771-80
pubmed: 25501577
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10
pubmed: 26960562
JCO Precis Oncol. 2020;4:382-392
pubmed: 32671317
J Clin Oncol. 2007 Feb 10;25(5):540-7
pubmed: 17290063
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Front Oncol. 2013 Aug 26;3:214
pubmed: 23986881
J Nucl Med. 2016 Dec;57(12):1858-1864
pubmed: 27516450
Theranostics. 2016 Jul 18;6(11):1821-32
pubmed: 27570553
Cancer Discov. 2013 Nov;3(11):1254-71
pubmed: 24027197
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
EJNMMI Res. 2018 Oct 29;8(1):96
pubmed: 30374743
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
Cancer. 2019 Aug 1;125(15):2561-2569
pubmed: 31012963
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
J Nucl Med. 2020 Jan;61(1):51-57
pubmed: 31253741
Lancet Oncol. 2012 Dec;13(12):1210-7
pubmed: 23142059
J Nucl Med. 2019 May;60(5):649-655
pubmed: 30413660
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Angew Chem Int Ed Engl. 2015 Sep 7;54(37):10778-82
pubmed: 26212031
J Clin Oncol. 2023 Nov 3;:JCO2300573
pubmed: 37922438
J Med Imaging Radiat Oncol. 2017 Jun;61(3):372-378
pubmed: 28116853
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Clin Oncol (R Coll Radiol). 2004 Feb;16(1):29-39
pubmed: 14768753
Nucl Med Commun. 2019 Jan;40(1):86-91
pubmed: 30395048
J Nucl Med. 2020 Jul;61(7):1030-1036
pubmed: 31806772
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
Eur Urol. 2018 Apr;73(4):485-487
pubmed: 29132714
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949
pubmed: 28138747
Appl Radiat Isot. 2013 Jun;76:55-62
pubmed: 23063597
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Mol Imaging Biol. 2015 Aug;17(4):575-84
pubmed: 26013479
J Nucl Med. 2015 Jun;56(6):914-20
pubmed: 25883127
JAMA Oncol. 2018 May 1;4(5):694-701
pubmed: 29522174
Nat Commun. 2019 Nov 7;10(1):5065
pubmed: 31699977
Semin Nucl Med. 2019 Jul;49(4):255-270
pubmed: 31227049
Oncotarget. 2018 Jun 19;9(47):28561-28571
pubmed: 29983880
Med Phys. 2013 Nov;40(11):112503
pubmed: 24320462
Semin Nucl Med. 2016 Nov;46(6):502-506
pubmed: 27825430
J Nucl Med. 2017 Jun;58(6):947-952
pubmed: 27908968
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Front Oncol. 2018 Jun 14;8:215
pubmed: 29963496
Eur J Nucl Med Mol Imaging. 2018 May;45(5):860-877
pubmed: 29335762
Clin Nucl Med. 2016 Jul;41(7):522-8
pubmed: 27088387
J Nucl Med. 2017 Dec;58(12):1943-1948
pubmed: 28619734
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910
pubmed: 31187162
Semin Radiat Oncol. 2020 Jan;30(1):4-15
pubmed: 31727299